Abstract Daily low-dose acetylsalicylacid (ASA) is prescribed to patients with atherothrombosis frequently to prevent vascular complications. In reports on complications and side effects of low-dose ASA use in the literature there is a range of definitions. We explored the incidence, characteristics and consequences of symptoms suggestive of ASA intolerance in patients on low-dose ASA.
The benefits of acetylsalicylacid (ASA) in the prevention of atherothrombosis have been well described in literature. 1 However, little is known about the incidence of symptoms and side effects of low-dose ASA use. Different studies have studied the efficacy and adverse effects of ASA, but have used a higher dose of ASA 2, 3 or reported only bleeding complications. 4, 5 In a study by Silagy et al., 6 the adverse effects of lowdose aspirin (100 mg daily) were studied in the elderly without pre-existing major vascular diseases in a doubleblind, randomised, placeboecontrolled trial. Gastrointestinal symptoms were reported by 18% of participants receiving aspirin (compared to 13% in the placebo group). Clinically evident gastrointestinal bleeding occurred in 3% of subjects receiving aspirin and none receiving placebo.
Definitions used for this phenomenon are: hypersensitivity, allergy, intolerance and interaction. Studies have estimated the prevalence between 5% and 36% depending on the definition used. 7, 8 Signs and symptoms of intolerance include dyspepsia and allergic rhinitis and more serious side effects such as gastric haemorrhage and/or perforation, bronchospasm and the exacerbation of asthma. 9, 10 The onset of side effects varies from days (skin rash) to months or even years (asthma or dyspepsia) after initiation of ASA therapy. Discontinuation of ASA therapy is associated with an increased risk of atherothrombotic complications. 11 In contrast to patients on a high dosage of ASA, the association between symptoms and the low dose of ASA might be underestimated by both patients and doctors.
We performed an observational study to estimate the prevalence of ASA intolerance in patients with a low-dose ( 120 mg) ASA monotherapy. The secondary goals of this study were to examine the signs and symptoms experienced by ASA-intolerant patients, the severity and duration of these signs and symptoms and the consequences. To investigate this in a large population, we approached patients over 40 years of age in 105 outpatient practices of either vascular surgeons, neurologists, internists or general practitioners.
Material and methods
From December 2006 to January 2008, investigators (vascular surgeons, neurologists, internists or general practitioners) in 105 centres in the Netherlands were asked to search their patients' files for the last 10 patients known to be prescribed low-dose ASA (Fig. 1 ). Ten consecutive Figure 1 Profile of the study. patients were selected who satisfied inclusion and no exclusion criteria. The consecutive method was chosen to prevent patient selection bias. Patients were invited to visit the clinic, during which visit the doctor interviewed the patient and completed the questionnaire. The start date of ASA use was documented. The doctor could include both chronic and recent users of ASA. Only patients who were already prescribed ASA treatment according to their files were included, which means that only those patients were included of which the participating doctors were convinced that they could tolerate ASA at the start of prescription.
Inclusion and exclusion criteria
Inclusion criteria for study participation were: (1) age over 40 years and (2) use of ASA or carbasalate calcium in a dosage of 30e120 mg per day. Patients were excluded from the study if ASA or carbasalate calcium was used in combination with other platelet aggregation inhibitors such as clopidogrel or dipyridamole.
ASA use
Information about duration of ASA use and daily dosage was obtained. Patients were asked if they were still taking ASA. If not, the reason to discontinue ASA treatment was obtained (from the following options): occurrence of side effects; increase of complaints; no effect of treatment; unclear necessity for ASA use; patient thinks ASA use is not required and other reasons to cease ASA use.
Contraindications for ASA use
The contraindications screened were: history of stomach problems or symptoms of stomach ache after previous ASA intake; history of peptic ulcer disease or gastrointestinal bleeding; allergy to salicylic acid or prostaglandin synthesis inhibitors; severe renal or hepatic insufficiency; history of haemorrhagic diathesis or coagulopathy.
Use of other medication
The use of co-medication was screened for the following drugs: antacids, oral anticoagulants and non-steroidal antiinflammatory drugs (NSAID).
General symptoms
Patients were asked for adverse effects during the full period of ASA use. When answered 'yes', these were further characterised by the following categories: symptoms of the upper respiratory tract, symptoms of blood and lymphoid system, skin or immune system and symptoms of the gastrointestinal tract.
Symptoms of the upper respiratory tract
Patients were screened for the existence of symptoms of the upper respiratory tract: nose bleedings; rhinitis; bronchospasms; asthma and other symptoms of the upper respiratory tract. If present, these symptoms were further characterised by duration, course and intensity.
Symptoms of the blood and lymphoid system, skin or immune system
Patients were screened for the existence of symptoms in blood and lymphoid system (thrombocytopaenia and anaemia), skin (rash and urticaria) and immune system (e.g., angio-oedema and allergy). Occurrence of thrombocytopaenia was documented.
Symptoms of the gastrointestinal tract
Patients were screened for the following gastrointestinal symptoms: epigastric discomfort; epigastric pain; vomiting; constipation; diarrhoea; gastrointestinal bleeding; gastric/ duodenal ulcer; epigastric burning/reflux; gastritis and other symptoms of the gastrointestinal tract.
To document these symptoms a questionnaire based on the ROME II criteria (Research Diagnostics Questions for functional gastrointestinal disorders) was used. 12 The questions in this list quantify the severity of the complaint by measuring the period and intensity of its occurrence.
Ethical considerations
The study did not necessitate any extra medical interventions. The investigators maintained all freedom to prescribe medication. No ethical approval of this study was needed according to Dutch law as subjects were not submitted to changes in medications or interventions. The data were collected anonymously. To protect the patient's privacy, only the year of birth was documented and a unique study number was assigned to the patient. The documented data can only be traced to the medical source data by the patients' own doctor.
Data analysis
Data are presented by descriptive statistics, consisting of means with standard deviation, median and range for continuous variables and numbers and percentages for categorical variables. Table 1 shows the baseline characteristics of the study population. The study included 957 patients from 105 centres. Although we chose the combination of ASA with another platelet aggregation inhibitor such as clopidogrel of dipyridamole as an exclusion criterion, 10 patients (1.1%) did not use ASA as monotherapy and were excluded from the analysis, which resulted in a total inclusion of 947 patients. The mean age of the patients was 68.3 years. More males than females were included (59.6% vs. 40.4%, respectively). The median ASA dosage used was 100 mg per day (range: 30e120 mg per day), for an average of 5.07 years. Sixty patients (6.6%) who were documented to use ASA, according to their file, appeared to have stopped using ASA, mostly because of occurrence of side effects (52%). Other reasons to cease ASA intake were increase of complaints (10%), no effect (3%), unclear necessity for ASA use (3%), the patient assumed ASA use is not required (3%) and other reasons to stop ASA (18%). Of these patients, 65% (39/60) terminated ASA use after 30 days.
Results

Patient characteristics
Contraindications of ASA and co-medication
The six questions considering contraindications of ASA use indicated that 13.7% of the patients reported a history of pain in the stomach region (Table 1) . Other contraindications to ASA, such as allergy to salicylic acid or prostaglandin synthesis inhibitors, severe kidney or liver insufficiency, intake of other platelet aggregation inhibitors and history of haemorrhagic diathesis or coagulopathy were uncommon. However, 7.1% of patients had a history of peptic ulcer disease or gastrointestinal bleeding. A quarter of the patients using daily low-dose ASA concomitantly used an anti-acid agent. Concomitant use of oral anticoagulants occurred in 5.2% of patients and/or use of other NSAID occurred in 6.6% of patients.
Occurrence of side effects
Over 30% of the included patients using ASA indicated the occurrence of side effects to the investigator. Twenty-nine patients (3.1%) experienced severe side effects. These were defined by the highest scores on the questionnaire considering astmatic (severe) or gastrointestinal (severe or highly severe) symptoms.
Eighty-nine patients (9.4%) reported side effects related to the upper respiratory tract (Table 2) . Asthma (23.6%) or nose bleedings (21.3%) formed a large part of this group, but most patients indicated other type of symptoms (39.3%) in this category. Almost half of the number of these patients had side effects for more than 2 years, but 30.1% only experienced problems shorter than 3 months. The side effects occurred less than once a week in half the number of cases. In our study, severe asthma was reported to occur in two patients, which, expressed as a proportion of all respiratory patients, amounted to 3.5% (2 of 57). Side effects considering the blood and lymphoid system were relatively rare (4.4%). Skin problems occurred in 70 patients (7.4%). In 38.6% of the cases, it concerned skin rash, but in most cases these symptoms were classified as other skin problems. Immune system side effects were very rare (0.7%). Angio-oedema occurred in three patients.
The results for gastrointestinal-related side effects are shown in Table 3 . These side effects were experienced in 25.1% of the patients (238 of 947 patients). Heartburn was reported most often (54.2%). Epigastric discomfort, gastritis and epigastric pain occurred in 20% of the patients. Nearly 40% of gastrointestinal side effects existed for more than 2 years. Considering the frequency of side effect occurrence, 61.0% of the patients experienced side effects only seldom. The course of side effects over time was stable. There was no difference in severity of gastrointestinal side effects throughout the previous 3 months in more than half the number of patients, and only 9.5% of patients reported that their situation had worsened. There were reports of mild gastrointestinal side effects in 52.6% of the patient population. Twelve patients experienced severe side effects. These patients suffered from gastrointestinal bleeding (two patients), peptic ulcer (three patients) and epigastric reflux/pain (seven patients). 
Discussion
This multicentre observational study in 947 patients who were prescribed a low dose of ASA suggests that approximately 30% of this population shows at least one sign of ASA intolerance. The most common side effects are associated with the gastrointestinal tract. Although most patients experienced mild symptoms, 5.6% of the patients with gastrointestinal side effects considered them as severe. A review of randomised controlled trials on the gastrointestinal toxicity of aspirin revealed that the pooled odds ratio (ORs) for categories of gastrointestinal bleeding were between 1.5 and 2.0. 8 The risk of peptic ulcer and upper gastrointestinal symptoms was increased (ORs 1.3 and 1.7, respectively). The review included mainly trials in which a higher dose of ASA was used (over 500 mg per day). It showed that toxicity of ASA use was dose related. Previous studies have demonstrated the benefit of a low dose of ASA in the secondary prevention of atherothrombosis. 1 Our study quantifies signs of gastrointestinal side effects in a population of patients prescribed a low dose of ASA. A recent study demonstrated that endoscopy in asymptomatic patients using a low dose of ASA showed haemorrhagic abnormalities in the duodenum or stomach in almost half the number of cases. 13 Although most patients with gastrointestinal side effects considered them to be mild, the clinical relevance of these symptoms becomes clear by the fact that a quarter of the patients on ASA also used an anti-acid agent. However, it remains unclear from our study if such an agent (ASA of anti-acid agent) was given for treatment or prevention.
In our study, 9.4% of the cases presented with side effects of the upper respiratory tract, such as asthma (23.6%). A large cohort study in Finland demonstrated that the risk of aspirin intolerance causing shortness of breath or asthma was 8.0 times higher in people with allergic rhinitis than without. 10 Bochenek et al. 14 showed that atopy is related to adverse drug reactions to NSAID. The mechanism of aspirin-precipitated asthma is thought to be related to the inhibition of cyclo-oxygenase (COX) and generation of cysteinyl leukotrienes in the respiratory tract of sensitive patients. 15 In our patient population, 60 had discontinued ASA treatment, more than half of them because of side effects. Treatment cessation by the patient without prior medical advice may be deleterious in patients at risk for atherothrombosis. In a meta-analysis, aspirin discontinuation or non-compliance was associated with a threefold higher risk of major cardiac events in patients with coronary artery disease. 11 This risk is even higher in patients with an intracoronary stent. Other platelet aggregation inhibitors have become available, with similar or even better results concerning the secondary prevention of atherothrombotic events. 2, 16 It is necessary that future studies focus on the differences in side effects of these agents compared to ASA. We could hypothesise that less intolerance with equal or better efficacy may become a reason to favour a new medicine over ASA in the secondary prevention of atherothrombosis.
It can be assumed that doctors would screen their patients for the presence of contraindications before prescribing ASA. In our study, 13.7% of patients reported gastric pain after previous use of ASA or a history of stomach complaints (Table 1 ). In a study by Silagy et al., 6 the adverse effects of low-dose aspirin (100 mg daily) in the elderly were studied over a 12-month period in a doubleblind, randomised, placeboecontrolled trial. In this study, 400 subjects were randomised to receive low-dose aspirin (100 mg daily) or placebo. Gastrointestinal symptoms were reported by 18% (n Z 36) of participants receiving aspirin (compared to 13% in the placebo group). The relatively high incidence may be due to the fact that the definition of the gastric contraindication leaves room for a considerable number of gastric clinical entities. However, if we look at the contraindication 'history of peptic ulcer disease or gastrointestinal bleeding' (7.1%), we can conclude that for a well-defined entity such as peptic ulcer disease or gastrointestinal bleeding, the reported incidence is still 7.1%. According to the prescribing information, these patients should never have started ASA use. The concomitant use of antacids, including proton pump inhibitors, in this study was reported to be 25.0% (226 of 906 patients). Two studies have compared aspirin to clopidogrel with antacid therapy. In the first study by Ng et al. 17 patients with aspirin-induced peptic ulcer disease treated with omeprazole (20 mg per day) were randomised to receive clopidogrel (75 mg per day) or to continue with lowdose aspirin. A minor gastrointestinal bleed was reported in 45% of the clopidogrel group and 42% of the aspirin group. The distributions of peptic ulcer disease were similar in the clopidogrel and aspirin groups. Using per protocol analysis, the treatment success rates of clopidogrel and aspirin were 94% (62 of 66) and 95% (57 of 60), respectively.
A second study by Chan et al. 18 compared clopidogrel alone with aspirin plus esomeprazole on the prevention of recurrent ulcer bleeding. The cumulative incidence of recurrent bleeding during the 12-month period was 8.6% (95% confidence interval (CI): 4.1e13.1%) among patients who received clopidogrel and 0.7% (95% CI: 0e2.0%) among those who received aspirin plus esomeprazole (difference: 7.9 percentage points; 95% CI for the difference: 3.4e12.4; p Z 0.001). A third group receiving clopidogrel plus esomeprazole was not included in this study. Both studies had great contributions to the knowledge about ASA treatment in combination with a proton pump inhibitor. However, in both studies, patients with known peptic ulcer disease or gastric bleeding were included. On that aspect, patients in those studies differed from our study population.
Our study has several limitations. First, to show that the symptoms addressed by patients using ASA are specific for ASA, it would be better to carry out a placeboecontrolled trial. However, with a placeboecontrolled trial, the patients in the placebo group would be withdrawn from essential medication (i.e., ASA) needed to prevent them from having a new atherothrombotic event. Placeboe controlled trials studying ASA intolerance would place patients potentially at risk and are, therefore, unethical. The aim of the study was to explore the magnitude of the occurrence of side effects of low-dose ASA in daily clinical practice. Our study demonstrates that even a low dose of ASA can induce symptoms suggestive of intolerance. Second, we did not conduct detailed descriptions of possible side effects of ASA. We mainly focussed on the symptoms that were most prevalent in our population, and further studies are needed to investigate the cause of these side effects. Third, despite its use in clinical practice, the ROME II criteria were developed to be used in epidemiological studies and not designed for this purpose. Lastly, there might be an additive effect of NSAID on the occurrence of side effects, which may increase the prevalence of ASA intolerance beyond its strict magnitude. However, only a relatively small part (6.6%) of the patients used ASA and NSAID.
In conclusion, side effects of low-dose daily ASA occur in a considerable number of patients. Patients and doctors need to be aware of a possible relationship between their symptoms and the use of ASA. This study shows that more attention to the occurrence of side effects after prescribing ASA may identify patients at risk. A proactive approach in the collection of information about adverse effects may be of benefit, because the occurrence of side effects is the most important reason for patients to discontinue ASA treatment, with a possible increase in atherothrombotic events. When adverse effects are suspected, doctors should either (1) treat the symptoms, for example, by prescribing antacids when gastrointestinal side effects occur or (2) advise against the use of ASA and initiate another platelet aggregation inhibitor.
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